Recro shares tank on FDA’s CRL; Prothena axes more than half of staff; Novo inks $200M deal with Epigen
→ Hard on the heels of the disastrous failure of its lead program, Prothena $PRTA is axing 57% of its staff, accounting for
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
